180160-47-8

Basic information

• Product Name: 5-chloro-3H-spiro[isobenzofuran-1,4'-piperidin]-3-one
• Synonyms: 5-chloro-3H-spiro[isobenzofuran-1,4'-piperidin]-3-one;5-Chlorospiro[isobenzofuran-1(3H),4'-piperidin]-3-one;5-CHLORO-3H-SPIRO[ISOBENZOFURAN-1,4'-PIPERIDIN]-3-ONE HCL
• CAS NO: 180160-47-8
• Molecular Formula: C12H12ClNO2
• Molecular Weight: 237.68218
• Mol File: 180160-47-8.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• Density: 1.37
• CAS DataBase Reference: 5-chloro-3H-spiro[isobenzofuran-1,4'-piperidin]-3-one(CAS DataBase Reference)
• NIST Chemistry Reference: 5-chloro-3H-spiro[isobenzofuran-1,4'-piperidin]-3-one(180160-47-8)
• EPA Substance Registry System: 5-chloro-3H-spiro[isobenzofuran-1,4'-piperidin]-3-one(180160-47-8)

Safety Data

• Hazardous Substances Data: 180160-47-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-chloro-3H-spiro[isobenzofuran-1,4'-piperidin]-3-one is used as a modulator for 11-β hydroxysteroid dehydrogenase type 1 (11-β HSD1) for the development of novel therapeutics. The modulation of this enzyme can potentially lead to the treatment of various conditions related to cortisol dysregulation, such as metabolic syndrome, type 2 diabetes, and obesity.
Used in Drug Development:
5-chloro-3H-spiro[isobenzofuran-1,4'-piperidin]-3-one is used as a lead compound in the design and synthesis of new drugs targeting 11-β HSD1. Its unique structure and activity make it a valuable starting point for the development of more potent and selective inhibitors or activators of this enzyme, which could have significant implications for the treatment of related diseases.
Used in Research Applications:
5-chloro-3H-spiro[isobenzofuran-1,4'-piperidin]-3-one serves as a valuable tool in the study of 11-β HSD1 enzyme function and its role in various physiological and pathological processes. Researchers can use this compound to investigate the enzyme's mechanisms of action, as well as to identify potential targets for therapeutic intervention in cortisol-related disorders.

Relevant articles and documents

CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF

Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: or physiologically acceptable salt thereof.